Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Short-term Investments (2023 - 2025)

GeneDx Holdings (WGS) has disclosed Short-term Investments for 3 consecutive years, with $66.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 18.42% to $66.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.3 million, a 18.42% increase, with the full-year FY2025 number at $66.3 million, up 18.42% from a year prior.
  • Short-term Investments was $66.3 million for Q4 2025 at GeneDx Holdings, up from $59.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $66.3 million in Q4 2025 to a low of $12.1 million in Q1 2023.
  • A 3-year average of $46.3 million and a median of $56.0 million in 2024 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: surged 140.77% in 2024, then grew 0.93% in 2025.
  • GeneDx Holdings' Short-term Investments stood at $30.5 million in 2023, then surged by 83.72% to $56.0 million in 2024, then grew by 18.42% to $66.3 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Short-term Investments are $66.3 million (Q4 2025), $59.1 million (Q3 2025), and $60.4 million (Q2 2025).